Does Insurance Cover TRT? Complete 2026 Coverage Guide

Testosterone Replacement Therapy (TRT) is one of the most common treatments for men with clinically low testosterone, also known as hypogonadism. While TRT has become increasingly accessible through telehealth platforms, insurance coverage remains a major hurdle for many patients. In 2026, the landscape of TRT insurance coverage is still complex, with strict medical necessity requirements, prior authorization (PA) processes, and formulation-specific restrictions.

Understanding how insurance works with TRT is critical. Even if your plan lists TRT as a covered benefit, you may still face denials due to improper diagnosis coding, missing lab results, or step therapy requirements. This comprehensive 2026 guide breaks down everything you need to know—from diagnosis criteria to insurer-specific policies—to help you navigate the system and get the treatment you need.

Diagnosis Requirements for TRT Coverage

To qualify for TRT coverage, insurers typically require a formal diagnosis of hypogonadism. This is not just about low testosterone levels—it is about proving that your low levels are causing clinically significant symptoms.

Hypogonadism Diagnosis Criteria

The Endocrine Society guidelines define hypogonadism as a condition where the testes fail to produce adequate testosterone. For insurance purposes, this diagnosis must be supported by:

• Two morning blood tests showing total testosterone levels below 300 ng/dL (drawn between 7 AM and 10 AM)
• Consistent symptoms of low testosterone — fatigue, low libido, erectile dysfunction, depression, reduced muscle mass, increased body fat
• Exclusion of secondary causes — pituitary tumors, chronic illness, opioid use, medication side effects

The 300 ng/dL Threshold

Most insurers use the 300 ng/dL threshold as their benchmark. If your testosterone is above this level, even with symptoms, you will likely be denied. Some insurers may consider borderline values (300–350 ng/dL) if symptoms are severe and lab results are consistent across two separate tests.

Blood tests must be drawn between 7 AM and 10 AM, as testosterone levels peak in the morning and decline throughout the day. Tests drawn after 10 AM may show falsely low results and can trigger additional scrutiny from insurers.

Prior Authorization Process for TRT

Prior authorization is required by nearly all major insurers before TRT is approved. Your provider must submit documentation to prove medical necessity before the pharmacy can fill the prescription.

1. Diagnosis and lab work: Your doctor confirms hypogonadism with two morning testosterone tests below 300 ng/dL
2. Documentation submission: Your provider sends a PA request with lab results, symptom history, and the correct diagnosis code (E29.1 for testicular hypofunction or E89.5 for postprocedural testicular hypofunction)
3. Insurer review: The insurer's medical review team evaluates the request — this typically takes 5–15 business days
4. Approval or denial: If approved, your prescription is authorized. If denied, you have the right to appeal

Common PA Issues That Cause Delays

• Missing or outdated lab results (tests older than 90 days)
• Incorrect diagnosis code — using E29.1 when E89.5 is more appropriate, or vice versa
• Insufficient symptom documentation in clinical notes
• Failure to document that non-hormonal alternatives were tried first
• Tests drawn outside the morning window (after 10 AM)

Which TRT Formulations Are Covered by Insurance?

Not all TRT formulations are treated equally by insurers. Coverage depends on the type of medication, whether a generic is available, and whether the insurer considers it medically necessary.

Formulation	Insurance Coverage	Typical Copay	Notes
Testosterone Cypionate (injectable, generic)	Yes — most insurers	$20–$50/month	The gold standard for insurance coverage. Generic 200mg/mL vial widely available.
Testosterone Enanthate (injectable, generic)	Yes — most insurers	$20–$50/month	Similar coverage to cypionate. Often interchangeable.
Testosterone Gels (AndroGel, Testim, generic)	Maybe — with PA and step therapy	$40–$100/month	Many insurers require trying injectables first. Brand-name gels face higher denial rates.
Testosterone Patches (Androderm)	Rarely covered	$60–$150/month	Higher cost, lower bioavailability. Most insurers exclude patches.
Testosterone Pellets (Testopel)	Rarely covered	$300–$600 per insertion	Most insurers classify pellets as experimental or elective. High denial rates.
Testosterone Nasal (Natesto)	Not covered	N/A	Niche formulation. Not on most formularies.

Insurer-Specific TRT Coverage in 2026

Aetna

• Covers generic injectable testosterone (cypionate/enanthate) with prior authorization
• Requires two morning labs below 300 ng/dL drawn at least 4 weeks apart
• Step therapy: must try injectable before gel approval is considered
• Does not cover pellets or nasal testosterone
• Typical copay: $25–$50/month on preferred generic tier

Cigna

• Covers injectable testosterone with PA
• Prefers diagnosis code E89.5 (postprocedural) over E29.1 (testicular hypofunction)
• Requires in-network lab testing
• Annual reassessment required — labs must be repeated every 12 months
• Gels covered only if injectables are documented as contraindicated

Blue Cross Blue Shield (BCBS)

• Coverage varies significantly by state and plan type
• Most employer-sponsored BCBS plans cover generic injectables with PA
• Some state plans cover gels if injectables are not tolerated (documentation required)
• Marketplace plans: coverage is inconsistent and often excludes TRT entirely
• Typical copay: $20–$40/month for generic injectables

UnitedHealthcare (UHC)

• Covers generic injectable testosterone with PA
• Requires two labs below 300 ng/dL plus documented symptoms
• Does not cover gels, pellets, or patches on most plans
• Some plans require a 6-month "observation period" before approval
• Formulary restricts to specific generic manufacturers

Medicare and Medicaid TRT Coverage

Medicare

• Part B covers injectable testosterone (cypionate/enanthate) administered in a physician's office as a medical benefit
• Part D covers self-administered injectable testosterone at a retail pharmacy (copay varies by plan)
• Requires diagnosis of hypogonadism with two documented low labs
• Does not cover gels, patches, or pellets under most Part D plans
• Patients pay 20% of the Medicare-approved cost after the Part B deductible

Medicaid

• Coverage varies by state — some states cover injectable TRT with PA, many do not
• States with coverage typically limit to generic cypionate or enanthate
• Some states require an endocrinologist referral before TRT approval
• Compounded testosterone is not covered under any state Medicaid program

The Age-Related Hypogonadism Exclusion Problem

One of the most common reasons for TRT denial is the "age-related hypogonadism" exclusion. Many insurers classify naturally declining testosterone in men over 40 as a normal aging process rather than a treatable medical condition.

To overcome this exclusion:

• Use the diagnosis code that best reflects the cause of low testosterone — E89.5 for primary hypogonadism is often more successful than E29.1
• Document specific symptoms and their impact on quality of life in clinical notes
• Include secondary lab work (LH, FSH, prolactin) to demonstrate pituitary-gonadal axis dysfunction
• Request a peer-to-peer review if initially denied — physicians can explain the clinical rationale directly

Step Therapy Requirements

Many insurers require step therapy before approving TRT. Common step therapy paths include:

1. Documentation of lifestyle interventions (exercise, weight loss, sleep optimization) for 3–6 months
2. Trial of injectable testosterone before gels or other formulations are approved
3. Trial of clomiphene citrate (off-label) before testosterone replacement in younger men

Step therapy can delay treatment by months. If your symptoms are severe, ask your provider to request an expedited PA or provide documentation of why step therapy is not appropriate.

Telehealth Clinics: The Insurance-Free Alternative

If your insurance denies TRT or the PA process is too burdensome, telehealth clinics offer a faster, more predictable path to treatment. These clinics provide all-inclusive monthly plans that include labs, medications, and ongoing monitoring — with no prior authorization required.

Top telehealth TRT providers in 2026:

• Hone Health: $100–$150/month all-in (labs, testosterone cypionate, provider visits, home delivery)
• Fountain TRT: $150/month including supplements and monitoring
• Peter Uncaged MD: $120/month with highly personalized protocols
• Defy Medical: $140/month with comprehensive hormone panels

If you have been denied TRT coverage or cannot get through the prior authorization process, a telehealth clinic may be your fastest path to treatment. Compare providers at MedSwitcher to find the best fit for your budget and goals.